CorMedix to Participate in Upcoming Investor Conferences

Rhea-AI Summary

CorMedix (NASDAQ:CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening conditions, announced its participation in two major healthcare investor conferences in September 2025.

The company's senior management will present at the Cantor Global Healthcare Conference on September 5 at 8:35am ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10 at 10:45am ET. Both presentations will be in a fireside chat format with webcasts available.

News Market Reaction – CRMD

+1.49%

+1.49% Session close to close

In the Aug 28 session, CRMD gained 1.49%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September.

Cantor Global Healthcare Conference

Date:	September 5, 2025
Time:	8:35am Eastern
Format:	Fireside Chat
Webcast:	Link to webcast

Morgan Stanley 23^rd Annual Global Healthcare Conference

Date:	September 10, 2025
Time:	10:45am Eastern
Format:	Fireside Chat
Webcast:	Link to webcast

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath^® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath^® in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix commenced clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath^® as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

FAQ

When is CorMedix (CRMD) presenting at the Cantor Global Healthcare Conference 2025?

CorMedix will present at the Cantor Global Healthcare Conference on September 5, 2025 at 8:35am Eastern in a fireside chat format.

What time is CorMedix's presentation at the Morgan Stanley Healthcare Conference 2025?

CorMedix will present at the Morgan Stanley Global Healthcare Conference on September 10, 2025 at 10:45am Eastern in a fireside chat format.

How can investors access CorMedix's (CRMD) conference presentations in September 2025?

Investors can access both presentations via webcasts that will be available for the Cantor and Morgan Stanley healthcare conferences.

Which investor conferences is CorMedix (CRMD) attending in September 2025?

CorMedix is attending two conferences: the Cantor Global Healthcare Conference on September 5 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025.